Melanoma includes cancers of the skin.

The Melanoma Disease Site Group (Melanoma DSG) produces evidence-based reports to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances. Reports produced by this group are available below.

• Systemic Adjuvant Therapy for Patients at High Risk for Recurrent Melanoma
  8-1 EBS Version 3.2009: June 2009 Rewrite
  
  • Practice Guideline
  • Evidence-Based Series
    July 2009: Section 2A of the EBS has been submitted to a peer-reviewed journal for publication and will be posted once it has been published.
    

• Biochemotherapy for the Treatment of Metastatic Malignant Melanoma
  8-3 EBS: April 2007
  
  • Practice Guideline
  • Evidence-Based Series
• Temozolomide for the Treatment of Metastatic Melanoma
  8-4 EBS: March 2006
  
  • Practice Guideline
  • Evidence-Based Series
• Single-Agent Interleukin-2 in the Treatment of Metastatic Malignant Melanoma
  8-5 EBS: March 2006
  
  • Practice Guideline
  • Evidence-Based Series